FACTS ARE NOT SYNERGISTIC WITH THE COMPANY ! Ha - Ha - Ha ----- Over $130 Billion ----- Ha - Ha - Ha ! There Aren't That Many Stupid People Out There, Eddie. This Company Has A Hard Time Just Getting $13M A Qtr. You Sure Don't Mind Coming Up With Stupid Numbers. And You Sure Don't Mind Coming Up With Stupid Stories. What Ever Happened To That $50M Per Qtr Rev Anyway ?
EPS: Neg 13 Cents + REV: Only $13M ---> WHAT HAPPENED !!!
You Know Eddie... I Use To Think You Were Just Naive. Then I Thought You Were Just Totally Ignorant To Reality. Finally I Came To The Conclusion That You Were Just Stupid. But Now I Realize That You Are Just A Sick Poser-Pumping-Fool.
That's The Game: Put A J.O. On A Message Board, And Then Have The Little-Paid-Poser-Pumping-Fool Come Up With Stupid Stories.
I Really Don't Mean To Be So Crass At Times, Eddie. But It's Only Proportional To The Junk That You Try To Spew. It's Comical How Far This Co Will Stoop, Trying To Trick People.
THE CAT IS OUT OF THE BAG Hey Eddie: Did you know that there is "Another Company" out there that has a different manufacturing procedure? They produce a similar End-Product, but it's based on another competitive proprietary patented technology. And the cost of manufacturing is much less. So the margins are way better. There is no comparison either, Eddie. Their clients are huge Global Firms that make these collaboration deals here look like nursery school rhymes.
And this "Other Company" has minimal working debt. They are well in the driver's seat with all of their current and prospective clients. It's more of a Win-Win. With no tricky or slick Financial shenanigans. Did you know that, Eddie? They are a Real "Private" Company too. Which means they don't have to "You Know What" any shareholders. Too bad they aren't public. I think they are also working on some kind of new additive for the beer market, as well. Something to do with alcohol-sugar & yeast. But it's not public yet.
I wonder if that's what's going on here? I wonder if this "Other Company" is stealing business away? I wonder if there is some renegotiations going on?
It seems to me that This Company here has been snookered into some bad collaboration deals. Those deals seem to be fixed-up, like: Toxic Dilutive Death Spiral Financing Packages. Did you know that, Eddie? It's like the failure to execute has always been in the cards.
So, it wasn't ever really about the product at all. It was always more on making money through the dirty Financing & Dilution end of things, while eventually going into another direction. Did you know that, Eddie? It looks more and more like some sort of set-up, or ploy. To take over a failing Company for other purposes altogether. Do you know what a "Ploy" is, Eddie ?
Do Some Deep DD On All That, Eddie And Let Me Know What You Come Up With
Item 1.01 Entry into a Material Definitive Agreement.
R&D Note Amendment
As previously reported, on March 21, 2016, in connection with the restructuring of the ownership and rights of Total Amyris BioSolutions B.V. (“ TAB ”), the joint venture between Amyris, Inc. (the “ Company ”) and Total Raffinage Chimie S.A., as assignee of Total Energies Nouvelles Activités USA (formerly known as Total Gas & Power USA, SAS) (“ Total ”), a commercial partner of the Company and an owner of greater than five percent of the Company’s outstanding common stock, the Company issued to Total a senior convertible note (the “ R&D Note ”) in the principal amount of $3.7 million. Subsequently, on February 27, 2017, the Company and Total entered into a first amendment to the R&D Note, pursuant to which the parties agreed to extend the maturity date of the R&D Note from March 1, 2017 to May 15, 2017. The restructuring of TAB and the issuance of the R&D Note were previously reported in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “ SEC ”) on March 24, 2016, and the first amendment to the R&D Note was previously reported in a Current Report on Form 8-filed by the Company with the SEC on March 3, 2017, each of which is incorporated herein by reference.
On May 15, 2017, the Company and Total entered into a second amendment to the R&D Note (the “ Second Amendment ”). Pursuant to the Second Amendment, the parties agreed to extend the maturity date of the R&D Note (the “ Maturity Date ”) from May 15, 2017 to March 31, 2018. In addition, the parties agreed to increase the interest rate on the amounts outstanding under the R&D Note from 1.5% to 12.0%, beginning May 16, 2017, together with a corresponding increase to the default interest rate. Lastly, pursuant to the Second Amendment, accrued and unpaid interest on the amounts outstanding under the R&D Note will be payable on December 31, 2017 and the Maturity Date.
As previously reported, on July 29, 2015, the Company entered into a Maturity Treatment Agreement with Total and Maxwell (Mauritius) Pte Ltd (“ Temasek ”), pursuant to which Total and Temasek agreed to convert certain convertible promissory notes of the Company held by them (the “ Remaining Notes ”) into shares of the Company’s common stock in accordance with the terms of such Remaining Notes on or prior to maturity, provided that certain events of default had not occurred with respect to the applicable Remaining Notes prior to such maturity. The entry into the Maturity Treatment Agreement was previously reported in a Current Report on Form 8-K filed by the Company with the SEC on July 30, 2015, which is incorporated herein by reference.
On May 15, 2017, the Company entered into a letter agreement with Total, pursuant to which the Company and Total agreed that the Company’s 6.50% Convertible Senior Notes due 2019 held by Total, in an aggregate principal amount of $9.7 million, would no longer be subject to mandatory conversion by Total at or prior to the maturity of such Remaining Notes. Accordingly, the Company will be required to pay any portion of such Remaining Notes that remain outstanding at maturity in cash in accordance with the terms of such Remaining Notes.
Biolding Note Amendment
As previously reported, on February 12, 2016, the Company entered into a Note and Warrant Purchase Agreement (the “ Purchase Agreement ”) for the sale of $18.0 million in aggregate principal amount of unsecured promissory notes (the “ Notes ”) and warrants to purchase 2,571,428 shares of the Company’s common stock at an exercise price of $0.01 per share (the “ Warrants ”) with certain purchasers, including Biolding Investment SA (“ Biolding ”), a fund affiliated with director HH Sheikh Abdullah bin Khalifa Al Thani, which purchased a Note in the principal amount of $2.0 million (the “ Biolding Note”) and Warrants to purchase 285,714 shares of the Company’s common stock. The entry into the Purchase Agreement and the issuance of the Notes and Warrants were previously reported in a Current Report on Form 8-K filed by the Company with the SEC on February 19, 2016, which is incorporated herein by reference.
On May 15, 2017, the Company and Biolding entered into a first amendment to the Biolding Note (the “ First Amendment ”). Pursuant to the First Amendment, the parties agreed to extend the maturity date of the Biolding Note from May 15, 2017 to November 15, 2017.
At over $130 Billion per year in future product revenues, it is safe to say that AMRS will blow the doors off, many major corporation on yearly product revenue. "If you are over 20 years old, and you have skin, you are one AMRS's customer." Good hunting people. Enjoy what is ahead!!
WHAT'S IT LIKE EDDIE ? What's It Like Being A Complete Idiot ?
EPS Was As Bad As It Can Get: Negative 13 Cents And Revenue Was A Complete Disaster: At $13M
Shame On You Eddie: For being on this Message Board with you rambling schizophrenic regurgitation of things you can't even understand, or don't have a clue about.
You are all over the map Eddie. You don't even know which side of the tracks to be on. You are a flip-flopper who wants to be right just once in your pathetic life.
You are the sum total of every stupid Pumping-Punk that roams these Boards. Feeding off of the irresponsible drivel that is supplied by lying twisted Companies like this one. Who's only way of survival is to lure in the unsuspecting naive stupidity of the masses.
You're An Idiot, Babe It's A Wonder That You Still Know How To Breathe
Ignore Eddy he is a nasty evil Troll under the bridge wolf in sheeps clothing want to pull wool over ur eyes steal your precious shares & fleece #$%$ you!
BIOSSANCE IS THE BIG COMPANY JOKE IN FACT IT'S A BIGGER JOKE THAN YOU Nothing Biossance Does Is Relevant To Anything. You Should Have Figured That Out By Now, Eddie. But Alas... You Are A Stupid & Mixed Up Pumper.
So Who Put You Up To All Of This Cut-n-Pasting BS Eddie ? Was It The Company? Was It FMR? The FSB Russian Mob ?
And Are You Even Aware Of The Recent Competition From Another Company That Will Drive This One Into Bankruptcy ?
Are You, Eddie ? ... Huh ? ... Are You ?
MAKING IT UP AS THEY GO ALONG Same Tactic From The Same Playbook
When the Company is a failure. When they can't make any revenues. When the EPS is a sinking ship. When projections turn out to be nothing but lies... What Then, Do You Do ?
Well... They get a couple JO's to post a bunch of nonsense on a message board. Then they try to associate Their Losing POS Company with Other Companies. Trying to act like they all have something in common.
BUT THEY DON'T HAVE ANYTHING IN COMMON It's All Just Part Of Their Normal Scam Routine
It's just another stupid way they try to fool you. It's the only version of a "Pump" they have left. That's Pretty Embarrassing! And what's even more embarrassing, is that they can't even afford to pay for a higher caliber of "Pumpers" !!! . . . LOL !
F I F T E E N - C E N T S
BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 20+ BAGGER POTENTIAL !!! AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .
Market Cap :US$ 11 Million Cash $4.1 Million << enough untill mid 2018 Price 0.18
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product Deals in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
Big merger in the chemical space, Huntsman-Clariant. That could be the reason behind today's push up. Quite obviously, if somebody wants to get a relevant position in green-chemistry/fermentation ... Then AMRS might be one of the best fits out there. Partner portfolio (Givaudan, Firmenich, DSM ...) is attractive as well. Just be patient. Not everything is bad in AMRS. Let's be patient (2 years patience). If they take the right steps, being in at 0.30 or 0.70 will make little difference in the end. Market cap is so low for a chemical player that this could easily be a 10 - 20 bagger. Be patient and stomach +/- 50% downs (and ups). It's the best house in a nascent neighborhood: green chemistry.
Long term this will be delisted but short term this stock is going to rocket on a bear rally bounce!
THERE ARE NO FACTS WHEN IT COMES TO THIS COMPANY Biossance Has A ZERO Total Effect On This Company. You Are A Complete Pumping AIRHEAD Fool, Eddie. Doesn't The Company Realize How Stupid They Are ? Cut-n-Paste Word-Games Don't Mean Squat Anymore.
And It's Too Late To Be Following The Same Idiotic Game Plan They Learned At The . . .
SHYSTER TRAINING SCHOOL FOR CEO's --- Chapter One: "How To Get Away With Larceny Without Really Trying"
You are An Idiot, Eddy. And I Don't Mind Telling You.
F I F T E E N - C E N T S
Verizon had an annual revenue in 2016 of $125,980,000. With over 4 Billion shares outstanding and stock price of $45.32 as of this posting, it will be peanuts when compare to AMRS's potential yearly revenue of over $130 billion and less than 300 million shares outstanding..
ROOSTER.... with nearly 300 million AMRS's shares on the open market, at a price of $0.30 or so, what's the volume traded as of this posting? Not even 450K shares. AMRS could be silicon valley's hidden germ. AMRS's debt and shares outstanding are peanuts when paired to a potential yearly revenue of over $130 billion from the biossance product sales line.
FYI AMRS just retired $86 million of their debt and it could be the tip of the iceberg.
*****Tuesday is Ceo Melo & new cfo girl time to shine!****** Remember ceo & cfo harvest 5 million off the top in total compensation. Amyris was $34.00 share to 30 cent while Amazon Tesla priceline chipotle went to the moon while Amyris cratered unbelievable king 5 million king ransom salary to melo & cfo girl. Bring rotten tomatoes to throw at shareholders meeting!
Too many lawsuits! Heavy losses, revenue not enough to make a dent on debt. Institutions share purchase support appears to be ZERO. Reverse split next week after the 23rd, 1:15 could bump the stock, then it will be diluted by management. Filing for Bankruptcy is a serious concern for AMRS, not saying that it will happen.
Protect your share cash.
This is screaming reverse split (I would bet on 10:1 - 15:1. All time lows, price discovery. I wouldn't touch it till we get a solid technical signal. It all comes to becoming cash flow positive. AMRS has solid partners, far from risking bankruptcy ... but the pace toward the absolute low might still be painful. Just be patient and never average down. I wouldn't buy till technicals point to the right direction. Consider reverse split kind of inevitable. Still very indebted company, further dilution ahead perfectly possible if they don't drive it to profitability in months to come.
Rodman Renshaw $4.00 share target Amyris I feel sick my last post today. P.s. What does the shiekh say e bout around $5 share I bought at $20.00 share remember when Amyris was $34.00 share! Unbelivable how melo get bbonus & raise for driving stock into the ground carol picknose compensation queen bee should ashamed!